Placebo + Seralutinib
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
Dec 28, 2023 → Dec 22, 2025
NCT ID
NCT05934526About Placebo + Seralutinib
Placebo + Seralutinib is a phase 3 stage product being developed by Gossamer Bio for Pulmonary Arterial Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT05934526. Target conditions include Pulmonary Arterial Hypertension.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07181382 | Phase 3 | Active |
| NCT05934526 | Phase 3 | Completed |
Competing Products
20 competing products in Pulmonary Arterial Hypertension